A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10 Dasom ChoiSoohyun LeeSangwook Yoon Leading Article 24 March 2022 Pages: 285 - 300
Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety Alok SinghMahesh Kumar Balasundaram Systematic Review 01 March 2022 Pages: 301 - 308
Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial Sarah SabryLamia Mohamed El WakeelMarwa Adel Ahmed Original Research Article Open access 10 March 2022 Pages: 309 - 318
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany Elena Rivero-FerrerMorten OlesenCristina Rebordosa Original Research Article Open access 15 March 2022 Pages: 319 - 331
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa Daniel Tobias MichaeliSophia StoychevaThomas Michaeli Original Research Article Open access 16 March 2022 Pages: 333 - 343
Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study Matteo RuggeriAlessandro SignoriniFilipa Aragão Original Research Article 17 March 2022 Pages: 345 - 354
Multiple Sclerosis Relapses Following Cessation of Fingolimod Charles B. MalpasIzanne Roosthe MSBase Study Group Original Research Article Open access 18 March 2022 Pages: 355 - 364
Tralokinumab in Atopic Dermatitis: A Profile of Its Use Hannah A. Blair Adis Drug Q&A 22 March 2022 Pages: 365 - 374
Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]‑BI 425809 in Healthy Males Ute BurkardMichael DeschTom S. Chan Correction Open access 14 March 2022 Pages: 375 - 375
